{"title":"Meeting Report","authors":"Daniel R. Dries","doi":"10.1042/bio_2023_138","DOIUrl":"https://doi.org/10.1042/bio_2023_138","url":null,"abstract":"","PeriodicalId":35334,"journal":{"name":"Biochemist","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135048295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Recent advances in designing safe and efficient viral vectors have spearheaded unprecedented growth in clinical trials and regulatory approvals for experimental gene therapies. Still, important challenges remain for gene therapies that require systemic administration into the circulation, including the patient’s immune response and the need for precise activation in the target cell population while sparing other tissues. Extensive research in engineering the vector’s external surface and genome has led to clever solutions, allowing novel in vivo therapies for previously untreatable genetic diseases such as spinal muscular atrophy and Duchenne muscular dystrophy to reach the clinic. In the future, we expect novel strategies, such as different viral vectors or non-viral delivery vehicles, to overcome the shortcomings of viral therapy.
{"title":"From unique challenges to inspired solutions: how vector engineering makes in vivo gene therapy possible","authors":"Rodanthi Lyraki","doi":"10.1042/bio_2023_127","DOIUrl":"https://doi.org/10.1042/bio_2023_127","url":null,"abstract":"Recent advances in designing safe and efficient viral vectors have spearheaded unprecedented growth in clinical trials and regulatory approvals for experimental gene therapies. Still, important challenges remain for gene therapies that require systemic administration into the circulation, including the patient’s immune response and the need for precise activation in the target cell population while sparing other tissues. Extensive research in engineering the vector’s external surface and genome has led to clever solutions, allowing novel in vivo therapies for previously untreatable genetic diseases such as spinal muscular atrophy and Duchenne muscular dystrophy to reach the clinic. In the future, we expect novel strategies, such as different viral vectors or non-viral delivery vehicles, to overcome the shortcomings of viral therapy.","PeriodicalId":35334,"journal":{"name":"Biochemist","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41939221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This issue focuses on one of the most keenly anticipated and researched topics in medicine – gene therapy. With recent advancements in the field, the hope is that some of the most debilitating diseases, many that seriously affect children, can begin to be treated.It wouldn’t be right to cover this topic in The Biochemist without also acknowledging the ethical considerations of these treatments. First, there are decisions to be made on what conditions might be ‘fixed’ via these methods, if they need fixing at all and what is the outcome for those that undergo these treatments? Although it is heartening to see developments in the treatment of diseases that can have serious life-limiting effects, who gets to decide which ones are prioritized for research?The second factor, which is discussed in a number of articles in this issue, relates to the cost of gene therapy treatments. Research has taken many years and a single-point treatment needs to cover costs, but the extraordinary level of finance required for one of these treatments also limits who has access. How can we make sure all who need it can receive it? Currently, gene therapy treatments are the most expensive treatment method across all medicine, with a single treatment costing millions of dollars.Lastly, the question is what comes next now that this technology is in use? What limits could/should there be (or not be) on the use of gene therapy?Biology, medicine and research are never in isolation from society and this is one area that highlights how important it is to have engagement and involvement from patients and the public, along with law and experts in the social sciences in the discussions of the creation, limits and applications of these approaches.The possibilities of gene therapy took longer than expected to be realized. Now different delivery methods of viral and non-viral vectors have been created to make the process more efficient and safer. The articles in this issue are looking at in vivo gene therapies, the challenges for the future and the steps that have taken us to where we are today.
{"title":"Gene therapy: yesterday, today and tomorrow","authors":"Heather Doran","doi":"10.1042/bio_2023_137","DOIUrl":"https://doi.org/10.1042/bio_2023_137","url":null,"abstract":"This issue focuses on one of the most keenly anticipated and researched topics in medicine – gene therapy. With recent advancements in the field, the hope is that some of the most debilitating diseases, many that seriously affect children, can begin to be treated.It wouldn’t be right to cover this topic in The Biochemist without also acknowledging the ethical considerations of these treatments. First, there are decisions to be made on what conditions might be ‘fixed’ via these methods, if they need fixing at all and what is the outcome for those that undergo these treatments? Although it is heartening to see developments in the treatment of diseases that can have serious life-limiting effects, who gets to decide which ones are prioritized for research?The second factor, which is discussed in a number of articles in this issue, relates to the cost of gene therapy treatments. Research has taken many years and a single-point treatment needs to cover costs, but the extraordinary level of finance required for one of these treatments also limits who has access. How can we make sure all who need it can receive it? Currently, gene therapy treatments are the most expensive treatment method across all medicine, with a single treatment costing millions of dollars.Lastly, the question is what comes next now that this technology is in use? What limits could/should there be (or not be) on the use of gene therapy?Biology, medicine and research are never in isolation from society and this is one area that highlights how important it is to have engagement and involvement from patients and the public, along with law and experts in the social sciences in the discussions of the creation, limits and applications of these approaches.The possibilities of gene therapy took longer than expected to be realized. Now different delivery methods of viral and non-viral vectors have been created to make the process more efficient and safer. The articles in this issue are looking at in vivo gene therapies, the challenges for the future and the steps that have taken us to where we are today.","PeriodicalId":35334,"journal":{"name":"Biochemist","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135464911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
In medical science, few areas hold as much promise and excitement as gene therapy. It is a cutting-edge field that aims to harness the body’s own genetic machinery to combat diseases at their root cause. While gene therapy has shown potential across various diseases (notably in rare monogenetic disease areas), here we dive into the latest advancements specifically focused on the heart. With cardiovascular diseases remaining a leading cause of global morbidity and mortality, researchers are tirelessly exploring innovative ways to tackle rare and common heart-related ailments. In this article, we discuss the fascinating world of gene therapy, exploring recent breakthroughs as well as remaining challenges and their implications for cardiovascular health.
{"title":"Healing hearts: unlocking the potential of gene therapy in revolutionizing cardiovascular disease treatment","authors":"A. Beqqali, A. Baker","doi":"10.1042/bio_2023_129","DOIUrl":"https://doi.org/10.1042/bio_2023_129","url":null,"abstract":"In medical science, few areas hold as much promise and excitement as gene therapy. It is a cutting-edge field that aims to harness the body’s own genetic machinery to combat diseases at their root cause. While gene therapy has shown potential across various diseases (notably in rare monogenetic disease areas), here we dive into the latest advancements specifically focused on the heart. With cardiovascular diseases remaining a leading cause of global morbidity and mortality, researchers are tirelessly exploring innovative ways to tackle rare and common heart-related ailments. In this article, we discuss the fascinating world of gene therapy, exploring recent breakthroughs as well as remaining challenges and their implications for cardiovascular health.","PeriodicalId":35334,"journal":{"name":"Biochemist","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45554140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Imagine starting life with a disease where the chances of reaching a fifth birthday are unlikely, let alone making it to adulthood, and the only treatments available are palliative at best. This is the reality facing millions of individuals born with a rare genetic disease. Sometimes, due to a single DNA base change – out of a possible 3 billion – occurring in the wrong place. A simple spelling mistake! However, recent years have seen the first effective gene therapies being developed, based on supplementing patient cells with functional copies of the faulty genes, or using antisense oligonucleotides or small molecules to alter pre-mRNA processing. The challenges were how to deliver genes or alter gene expression in the diseased cells and how to do it safely, without negatively affecting other endogenous genes. The answers came in the form of viruses, small non-coding RNAs and bacterial proteins, which is somewhat ironic, because we are using infectious agents or mimetics of their products to help cure diseases. With old enemies turned allies, tool sets are now being assembled to tackle the most challenging of genetic diseases. This article explores some of those tool chests in further detail, using ataxia telangiectasia, spinal muscular atrophy and several other rare diseases to highlight progress and challenges.
{"title":"Foes to friends: do pathogens hold the key to gene therapy?","authors":"M. Pearson, Rafael J. Yáñez-Muñoz","doi":"10.1042/bio_2023_131","DOIUrl":"https://doi.org/10.1042/bio_2023_131","url":null,"abstract":"Imagine starting life with a disease where the chances of reaching a fifth birthday are unlikely, let alone making it to adulthood, and the only treatments available are palliative at best. This is the reality facing millions of individuals born with a rare genetic disease. Sometimes, due to a single DNA base change – out of a possible 3 billion – occurring in the wrong place. A simple spelling mistake! However, recent years have seen the first effective gene therapies being developed, based on supplementing patient cells with functional copies of the faulty genes, or using antisense oligonucleotides or small molecules to alter pre-mRNA processing. The challenges were how to deliver genes or alter gene expression in the diseased cells and how to do it safely, without negatively affecting other endogenous genes. The answers came in the form of viruses, small non-coding RNAs and bacterial proteins, which is somewhat ironic, because we are using infectious agents or mimetics of their products to help cure diseases. With old enemies turned allies, tool sets are now being assembled to tackle the most challenging of genetic diseases. This article explores some of those tool chests in further detail, using ataxia telangiectasia, spinal muscular atrophy and several other rare diseases to highlight progress and challenges.","PeriodicalId":35334,"journal":{"name":"Biochemist","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49094162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The 156 attendees from 20 countries, dominated by PhD students (53 attendees) and postdoctoral scientists (50), helped create a rich programme of cutting-edge science delivered through 100 posters, 39 offered talks (including mini, short and extended talks) and 19 invited speakers. Sponsorship from the Biochemical Society contributed to an enormously successful event.The programme began with keynote speaker Stefan Raunser (Max Planck Institute of Molecular Physiology, Germany) who summarized a decade of discoveries involving Tc toxin produced by the bacterial pathogen Photorhabdus luminescens. ETOX 2023 showcased two further keynotes who presented exciting advances in antibacterial effector proteins (Chris Hayes, University of California, USA) and Samonella genotoxins (Teresa Frisan, University of Umeå, Sweden).The impact of cryogenic electron microscopy emerged as a key point of interest, as the approach was exploited to reveal new atomic structures of toxins or their delivery systems by scientists such as Martin Pilhofer and David Albesa-Jové. Another key takeaway from ETOX 2023 was the pace of discoveries on bacterial type 6 secretion systems: how they are used by pathogens to deploy toxins that kill bacterial competitors or eukaryotic host cells or influence the surrounding microbiota for pathogen survival. Exciting mechanisms underlying innate immunity and subversion by pathogens were introduced by researchers such as Feng Shao, Neal Alto, Charlotte Odendall and Teresa Thurston. Early career researchers made an enormous contribution to the meeting and lit up the scientific programme with 21 talks including prize winners Rachel Prescott, Marila Torrado, Mohamed ElGhazaly, Tom Arrowsmith, Christy Cheung and Charles Ericson.After a final day of excursions in the Scottish Highlands, a conference dinner, Ceilidh dance and prize giving, the meeting closed with a final announcement – the location of ETOX 2025 in Bilbao, Spain!
{"title":"Meeting reports","authors":"Daniel Humphreys, Sarah Coulthurst","doi":"10.1042/bio_2023_133","DOIUrl":"https://doi.org/10.1042/bio_2023_133","url":null,"abstract":"The 156 attendees from 20 countries, dominated by PhD students (53 attendees) and postdoctoral scientists (50), helped create a rich programme of cutting-edge science delivered through 100 posters, 39 offered talks (including mini, short and extended talks) and 19 invited speakers. Sponsorship from the Biochemical Society contributed to an enormously successful event.The programme began with keynote speaker Stefan Raunser (Max Planck Institute of Molecular Physiology, Germany) who summarized a decade of discoveries involving Tc toxin produced by the bacterial pathogen Photorhabdus luminescens. ETOX 2023 showcased two further keynotes who presented exciting advances in antibacterial effector proteins (Chris Hayes, University of California, USA) and Samonella genotoxins (Teresa Frisan, University of Umeå, Sweden).The impact of cryogenic electron microscopy emerged as a key point of interest, as the approach was exploited to reveal new atomic structures of toxins or their delivery systems by scientists such as Martin Pilhofer and David Albesa-Jové. Another key takeaway from ETOX 2023 was the pace of discoveries on bacterial type 6 secretion systems: how they are used by pathogens to deploy toxins that kill bacterial competitors or eukaryotic host cells or influence the surrounding microbiota for pathogen survival. Exciting mechanisms underlying innate immunity and subversion by pathogens were introduced by researchers such as Feng Shao, Neal Alto, Charlotte Odendall and Teresa Thurston. Early career researchers made an enormous contribution to the meeting and lit up the scientific programme with 21 talks including prize winners Rachel Prescott, Marila Torrado, Mohamed ElGhazaly, Tom Arrowsmith, Christy Cheung and Charles Ericson.After a final day of excursions in the Scottish Highlands, a conference dinner, Ceilidh dance and prize giving, the meeting closed with a final announcement – the location of ETOX 2025 in Bilbao, Spain!","PeriodicalId":35334,"journal":{"name":"Biochemist","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135262869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aga Gambus, Matthias Soller, Ferenc Mueller, Constanze Bonifer
The 6th BCGB Symposium on Genome Structure and Function, at the University of Birmingham, was a great success.The selling point of our meeting was to bring together researchers from across the region interested in various aspects of genome biology – from chromatin organization and gene expression to DNA replication and genome stability.The science was amazing, delegates enthusiastic and happy to network in person. We had over 150 participants, mainly early career researchers (ECRs), who enjoyed networking with our two keynote speakers: Ellen Rothenberg (CalTech) and Dan Tenen (Harvard University), who joined us from the USA. We had 11 invited speakers from all over the UK and EU and 13 elevated abstracts talks, which were delivered in majority by ECRs. We also had two flash poster sessions, which were excellent and acted as a great advertisement for the three poster sessions held.Most of the science presented was new and unpublished and we could appreciate the novel technologies and the emerging concepts in genome biology. The science presented and discussed also covered a wide spectrum of biomedical research – from structural protein biology to clinical trials. We all have learned a lot, and this variety of genome biology science certainly opened the horizon for many of the ECRs attending.Find out more about the event and programme here.
{"title":"Meeting Reports","authors":"Aga Gambus, Matthias Soller, Ferenc Mueller, Constanze Bonifer","doi":"10.1042/bio_2023_134","DOIUrl":"https://doi.org/10.1042/bio_2023_134","url":null,"abstract":"The 6th BCGB Symposium on Genome Structure and Function, at the University of Birmingham, was a great success.The selling point of our meeting was to bring together researchers from across the region interested in various aspects of genome biology – from chromatin organization and gene expression to DNA replication and genome stability.The science was amazing, delegates enthusiastic and happy to network in person. We had over 150 participants, mainly early career researchers (ECRs), who enjoyed networking with our two keynote speakers: Ellen Rothenberg (CalTech) and Dan Tenen (Harvard University), who joined us from the USA. We had 11 invited speakers from all over the UK and EU and 13 elevated abstracts talks, which were delivered in majority by ECRs. We also had two flash poster sessions, which were excellent and acted as a great advertisement for the three poster sessions held.Most of the science presented was new and unpublished and we could appreciate the novel technologies and the emerging concepts in genome biology. The science presented and discussed also covered a wide spectrum of biomedical research – from structural protein biology to clinical trials. We all have learned a lot, and this variety of genome biology science certainly opened the horizon for many of the ECRs attending.Find out more about the event and programme here.","PeriodicalId":35334,"journal":{"name":"Biochemist","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135263389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gene therapy is emerging as the realistic treatment option for inborn errors of metabolism (IEMs) and, with the promising safety and efficacy evidence from the proof-of-concept studies, adeno-associated virus (AAV) has become the frontrunner among viral vector candidates for these monogenic disorders. Different AAV capsids exhibit specific tissue tropisms, which can considerably increase the efficiency of gene transfer to particular organs. Here, we will discuss two distinct diseases: ornithine transcarbamylase (OTC) deficiency and Niemann–Pick disease type C, in which significant advances have been achieved in AAV-based gene therapy trials.
{"title":"AAV-mediated gene therapy for rare metabolic disorders: turning a promise into a reality","authors":"B. Şeker Yılmaz, P. Gissen","doi":"10.1042/bio_2023_128","DOIUrl":"https://doi.org/10.1042/bio_2023_128","url":null,"abstract":"Gene therapy is emerging as the realistic treatment option for inborn errors of metabolism (IEMs) and, with the promising safety and efficacy evidence from the proof-of-concept studies, adeno-associated virus (AAV) has become the frontrunner among viral vector candidates for these monogenic disorders. Different AAV capsids exhibit specific tissue tropisms, which can considerably increase the efficiency of gene transfer to particular organs. Here, we will discuss two distinct diseases: ornithine transcarbamylase (OTC) deficiency and Niemann–Pick disease type C, in which significant advances have been achieved in AAV-based gene therapy trials.","PeriodicalId":35334,"journal":{"name":"Biochemist","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43590198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Potential impact is an important driver in the career choices and journeys of many. There have even been organizations set up to help people make career decisions that can boost their global impact, such as ‘80000hours.org’. Impact has always been an important motivator for me in my decisions; however, I often find myself feeling helpless to make a significant impact through my research. Informing policymaking is an activity where scientists can use their expertise to have a beneficial impact, but how to engage with policymakers can be unclear. This is why I was so excited to have been invited to attend the Royal Society of Biology’s 2023 Parliamentary Links Day on Science and Economic Development. ‘The best way to make an impact is to join scientific advisory councils and panels” was the most important recommendation I took home with me following the event; advice which helped me walk away with more clarity on how I can be impactful.
{"title":"The value of the ‘Science and Economic Development’ Parliamentary Links Day 2023","authors":"Calum Upton","doi":"10.1042/bio_2023_130","DOIUrl":"https://doi.org/10.1042/bio_2023_130","url":null,"abstract":"Potential impact is an important driver in the career choices and journeys of many. There have even been organizations set up to help people make career decisions that can boost their global impact, such as ‘80000hours.org’. Impact has always been an important motivator for me in my decisions; however, I often find myself feeling helpless to make a significant impact through my research. Informing policymaking is an activity where scientists can use their expertise to have a beneficial impact, but how to engage with policymakers can be unclear. This is why I was so excited to have been invited to attend the Royal Society of Biology’s 2023 Parliamentary Links Day on Science and Economic Development. ‘The best way to make an impact is to join scientific advisory councils and panels” was the most important recommendation I took home with me following the event; advice which helped me walk away with more clarity on how I can be impactful.","PeriodicalId":35334,"journal":{"name":"Biochemist","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48195386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Each year, the Biochemical Society fully sponsors the attendance of two outstanding postgraduate or early career members to attend the Federation of European Biochemical Societies (FEBS) Congress and Young Scientists’ Forum (YSF). With a theme of ‘Together in bioscience for a better future’, the 47th FEBS Congress and 22nd YSF combined research presentations, general talks and practical career exercises to showcase the newest developments in biochemistry, molecular biology and related areas. Providing an incredible opportunity to make connections with European colleagues and discuss research with an international audience, we were delighted to offer International Sponsored Places to Dr Yang Li (University College London, UK) and Dr Ewa Blaszczak (Medical University of Lublin, Poland) in 2023. Here, Yang and Ewa discuss their experiences at this year’s meetings and highlight the valuable networking and interactions developed as a result of their participation.
{"title":"International Sponsored Places: 47th FEBS Congress and 22nd Young Scientists’ Forum 2023","authors":"Lucy Ollett","doi":"10.1042/bio_2023_136","DOIUrl":"https://doi.org/10.1042/bio_2023_136","url":null,"abstract":"Each year, the Biochemical Society fully sponsors the attendance of two outstanding postgraduate or early career members to attend the Federation of European Biochemical Societies (FEBS) Congress and Young Scientists’ Forum (YSF). With a theme of ‘Together in bioscience for a better future’, the 47th FEBS Congress and 22nd YSF combined research presentations, general talks and practical career exercises to showcase the newest developments in biochemistry, molecular biology and related areas. Providing an incredible opportunity to make connections with European colleagues and discuss research with an international audience, we were delighted to offer International Sponsored Places to Dr Yang Li (University College London, UK) and Dr Ewa Blaszczak (Medical University of Lublin, Poland) in 2023.\u0000 Here, Yang and Ewa discuss their experiences at this year’s meetings and highlight the valuable networking and interactions developed as a result of their participation.","PeriodicalId":35334,"journal":{"name":"Biochemist","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44501125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：